Dr Gholam on Camrelizumab Plus Rivoceranib in Unresectable HCC

Pierre Gholam, MD, discusses findings from the phase 3 CARES-310 trial of camrelizumab plus rivoceranib in patients with unresectable hepatocellular carcinoma.

Related Keywords

United States ,Pierre Gholam ,Digestive Health Research Institute ,Department Of Medicine ,Case Western Reserve University ,School Of Medicine ,D ,Cares 310 Trial ,Nct03764293 ,Camrelizumab Plus Rivoceranib ,Patients With Unresectable Hepatocellular Carcinoma ,